Michael W Bonney has an estimated net worth of $69 Million. This is based on reported shares across multiple companies, which include BRISTOL MYERS SQUIBB CO, ALNYLAM PHARMACEUTICALS, INC., Kaleido Biosciences, Inc., Sarepta Therapeutics, Inc., H&Q HEALTHCARE INVESTORS, Tekla Healthcare Opportunities Fund, Tekla World Healthcare Fund, H&Q LIFE SCIENCES INVESTORS, Global Blood Therapeutics, Inc., Magenta Therapeutics, Inc., Syros Pharmaceuticals, Inc., CELGENE CORP /DE/, NPS PHARMACEUTICALS INC, CUBIST PHARMACEUTICALS INC, and Autolus Therapeutics plc.

2019 was Michael W Bonney's most active year for acquiring shares with 27 total transactions. Michael W Bonney's most active month to acquire stocks was the month of May. 2015 was Michael W Bonney's most active year for disposing of shares, totalling 21 transactions. Michael W Bonney's most active month to dispose stocks was the month of April. 2012 saw Michael W Bonney paying a total of $8,470,739.51 for 277,103 shares, this is the most they've acquired in one year. In 2015 Michael W Bonney cashed out on 1,969,045 shares for a total of $19,370,884.00, their largest year based on trade value.